ArticleACS omega2026
Dual Roles of hABCB1 in Drug Resistance and Immune Evasion: Implications for Lung Cancer Therapy.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance mediated by ATP-binding cassette transporter B1 (ABCB1) remains a major obstacle in nonsmall cell lung cancer (NSCLC) therapy. While its role in drug efflux is well established, whether elevated ABCB1 expression is associated with broader immune-related phenotypes has not been completely elucidated. Here, we examined hABCB1-overexpressing and drug-adapted NSCLC models to assess coordinated changes in drug resistance and immune susceptibility. Increased ABCB1 expression was associated with enhanced efflux activity and reduced sensitivity to chemotherapeutic agents. Across engineered and drug-selected systems, ABCB1-high cells showed decreased susceptibility to NK-92-mediated cytotoxicity. Pharmacological inhibition of transporter activity partially increased effector-mediated killing, supporting ABCB1 activity as a contributing factor, while indicating that additional mechanisms may also be involved. Proteomic and cytokine profiling suggested coordinated alterations in inflammatory and interferon-related signaling pathways. In a human lung cancer tissue microarray, elevated hABCB1 expression was inversely associated with CD3
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.